DCVMN Pharmacovigilance WG 2022
Key Learnings & Activities

Viska Indriani, PT Biofarma
Co-Chair of the DCVMN Pharmacovigilance WG
DCVMN Commitment to Pharmacovigilance

- The DCVMN Pharmacovigilance WG goal is to increase and strengthen pharmacovigilance (PV) capacities and to enhance vaccine safety monitoring to implement a mature “fit for purpose” PV System.
- The pharmacovigilance WG ensures the DCVMN members are equipped with up-to-date knowledge to implement best practices and training aligned with WHO and relevant national regulatory requirements.
DCVMN Pharmacovigilance Working Group

• Discuss the evolving Pharmacovigilance landscape to identify the needs of DCVMN members and share successful case studies.

• Provide access to external expertise (webinars, workshops, trainings).

• Create ad hoc projects or relevant projects which could benefit from DCVMN participation.

10 companies from
• Brazil
• China
• India
• Indonesia
• South Africa
• Vietnam
DCVMN Pharmacovigilance WG
Areas of Focus 2022

- Finalization of the Risk Management Plan project
- Continuation of PV post-licensure training with PATH
- Pre-licensure period: Clinical Safety Management
- Active Vaccine Safety Surveillance
- Electronic Safety Data Management
Risk Management Plan Project

- Aimed to strengthen the capacity of DCVMs for the development of risk management plans (RMPs) for vaccine registration and PQ submissions to meet the ICH Guidelines.
- **9 DCVMN member companies** took part in online workshops and active Risk Management Plan preparation exercise.
- Submitted Risk Management Plans were evaluated by DCVMN consultants with 1-1 feedback.
- Culmination of project was a final webinar and publication of DCVMN Risk Management Plan guidance document ([RMP project - General Comments (dcvmn.net)](RMP project - General Comments (dcvmn.net)))
Continuation of post-licensure training with PATH

- Held 3 online workshop trainings presented by PATH consultant to pharmacovigilance WG on MedDRA Coding Best practices, Data retrieval and Presentation (Training workshop materials – DCVMN)

<table>
<thead>
<tr>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td><strong>Objectives</strong></td>
<td></td>
</tr>
<tr>
<td>Medical Coding Term Selection Best Practices – Part 1</td>
<td>To introduce MedDRA® TERM SELECTION: POINTS TO CONSIDER document and cover important aspects related to: 1. General term selection procedures 2. Important term selection points</td>
<td>Continue presentation on the important term selection points</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To introduce MedDRA® DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER document and cover important aspects from this guideline</td>
</tr>
</tbody>
</table>
Clinical Development & Medical Affairs WG Collaboration

• Joint Face-to-Face Workshop held in June 2022 to discuss the role of Pharmacovigilance activities in clinical aspects of vaccines in pre- and post-licensure:
  ▪ Stakeholders in Clinical Trial Safety Management
  ▪ Systematic approach to patient safety
  ▪ Pharmacovigilance Clinical Trials Guidelines
  ▪ Safety assessments in Clinical Trials
  ▪ Signal and Benefit-Risk Management

• From this meeting the Pharmacovigilance WG published a Pharmacovigilance specific SOP Master List with Explanatory Notes for the Pharmacovigilance activities in the pre- and post-licensure period
Active Vaccine Safety Surveillance

- **Goal:** Strengthen active vaccine safety surveillance activities and capacities, and to support implementation.
- 2 day online training to support the creation of own AVSS plans.
- DCVMN Participant plans will be reviewed by DCVMN expert consultants with feedback.
- Training and outcomes will also be published on DCVMN moodle for future members.
Electronic Safety Data Management Systems

• **Goal:** Outline electronic safety data management systems and support adoption and implementation of such systems.

• Submit for publication a paper providing a holistic view on the requirements for adoption and implementation of an electronic safety data management system

• Distribute a DCVMN electronic safety data management systems acquisition tool and RfP template to assist members in acquiring system best suited to member needs.
Pharmacovigilance WG Key Learnings

• Trainings and direct experience through direct access to expertise and promote adoption of new approaches to pharmacovigilance.
• Pharmacovigilance activities are increasing for DCVMN members and extend throughout entire life-cycle of products including pre-clinical safety aspects relevant to humans.
• Internal collaboration and shared experience facilitate engagement and planning.